Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
ApexOnco Front Page
Recent articles
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The biotech licenses a China-developed anti-B7-H3 ADC.
Armed with $75m the company takes a risky asset into the clinic.
GEN1286 looks dead, though MCLA-129 continues for now.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
